Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
Medicus Pharma Ltd. announced the submission of an optimized Phase 2 clinical study protocol for Teverelix, its investigational GnRH antagonist, to the U.S. FDA. The study targets prevention of recurrent acute urinary retention in men with benign prostatic hyperplasia. The new study design reduces sample size and cost, aiming for rapid generation o…